Learn more about our new preclinical data published in Nature, demonstrating long-term survival with genetically engineered porcine kidneys.


Steven Gillis, Ph.D.

Board Chairman

Dr. Steven Gillis is a managing director at ARCH Venture Partners, focused on the evaluation of new life science technologies and the development and growth of ARCH’s biotechnology portfolio companies. In addition to eGenesis, he is also director of Homology Medicines, Inc., Allozyne, Pulmatrix (PULM), Codiak Biosciences, Faraday Pharmaceuticals, Just. Biotherapeutics, VLST, and Accelerator. He serves as director and Chairman of VentiRx Pharmaceuticals, Theraclone Sciences, Lycera, VBI Vaccines (VBIV), and PhaseRx.

Dr. Gillis is an immunologist by training with over 300 peer-reviewed publications in the areas of molecular and tumor immunology. He received a B.A. from Williams College and a Ph.D. from Dartmouth College.

Steven Gillis